@article{pastina_early_bergman_nettifee_maller_bray_waldron_castel_munana_papich_et al._2018, title={The pharmacokinetics of cytarabine administered subcutaneously, combined with prednisone, in dogs with meningoencephalomyelitis of unknown etiology}, volume={41}, ISSN={["1365-2885"]}, url={https://doi.org/10.1111/jvp.12667}, DOI={10.1111/jvp.12667}, abstractNote={Abstract The objective of this study was to describe the pharmacokinetics (PK) of cytarabine (CA) after subcutaneous (SC) administration to dogs with meningoencephalomyelitis of unknown etiology (MUE). Twelve dogs received a single SC dose of CA at 50 mg/m 2 as part of treatment of MUE. A sparse sampling technique was used to collect four blood samples from each dog from 0 to 360 min after administration. All dogs were concurrently receiving prednisone (0.5–2 mg kg −1 day −1 ). Plasma CA concentrations were measured by HPLC, and pharmacokinetic parameters were estimated using nonlinear mixed‐effects modeling (NLME). Plasma drug concentrations ranged from 0.05 to 2.8 μg/ml. The population estimate (CV%) for elimination half‐life and Tmax of cytarabine in dogs was 1.09 (21.93) hr and 0.55 (51.03) hr, respectively. The volume of distribution per fraction absorbed was 976.31 (10.85%) ml/kg. Mean plasma concentration of CA for all dogs was above 1.0 μg/ml at the 30‐, 60‐, 90‐, and 120‐min time points. In this study, the pharmacokinetics of CA in dogs with MUE after a single 50 mg/m 2 SC injection in dogs was similar to what has been previously reported in healthy beagles; there was moderate variability in the population estimates in this clinical population of dogs.}, number={5}, journal={Journal of Veterinary Pharmacology & Therapeutics}, publisher={Wiley}, author={Pastina, B. and Early, P.J. and Bergman, R.L. and Nettifee, J. and Maller, A. and Bray, K.Y. and Waldron, R.J. and Castel, A.M. and Munana, K.R. and Papich, M.G. and et al.}, year={2018}, month={Oct}, pages={638–643} }